key: cord-0959232-pr3pdsut authors: Marcatili, Matteo; Stefana, Alberto; Colmegna, Fabrizia; di Giacomo, Ester; D'Amico, Emiliano; Capuzzi, Enrico; Dakanalis, Antonios; Clerici, Massimo title: Consultation psychiatry in COVID‐19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs date: 2021-02-25 journal: Psychiatry Clin Neurosci DOI: 10.1111/pcn.13205 sha: bac63d64525b1a8a5521a181cf9a6de531bfc62c doc_id: 959232 cord_uid: pr3pdsut nan 1 Inhibition of the cytochrome P450 isoforms implicated in the metabolism of psychoactive drugs. This inhibition can reduce the clearance of many antidepressants, antipsychotics, and anxiolytics, increasing plasma concentrations of the main molecules and related major active metabolites that, in turn, will be able to exert therapeutic or collateral effects depending on the level and type of inhibition.In this mechanism, all protease inhibitors are involved but, for the reasons mentioned above, ritonavir is obviously the main actor. It is responsible for the main psychiatric contraindications indicated in the product labeling information (i.e., lurasidone, pimozide, quetiapine, midazolam, and triazolam) through its strong inhibition of CYP-3A4 but many other clinically relevant interactions with antidepressants and antipsychotics have been described in the literature 7 and many others can be deduced.Almost all monoaminergic modulators, such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants, can be affected by these interactions (see Table S1 ). 2 Induction of the cytochrome P450 isoforms implicated in the metabolism of psychoactive drugs. This induction can increase the clearance of different drugs, decreasing their plasma concentrations and, probably, the resulting clinical efficacy. Ritonavir has been shown to induce CYP-2B6 (e.g., bupropion), CYP-1A2 (e.g., olanzapine), and UDP-glucuronyltransferases (e.g., lamotrigine and valproate; see Table S1 ). 3 Induction of the cytochrome P450 isoforms implicated in the metabolism of antivirals and reciprocal effects. Protease inhibitors are also substrates of cytochrome activities and their levels can be modulated by inhibitors or inductors. Lopinavir levels and other antivirals can be decreased by different inducers.In the psychiatric context, the principal agent is Hypericum perforatum (St. John's wort), a herbal medicine used for its possible antidepressant activity and a potent inducer of CYP-3A4. Coadministration with St. John's wort may significantly reduce the plasma concentrations of HIV protease inhibitors and result in a potential loss of virologic response. 8 Coadministration with carbamazepine was reported to be particularly complex and unpredictable, as its induction on CYP-3A4 is potentially able to decrease protease inhibitor concentrations with the resulting potential antiretroviral resistance and treatment failure, and its levels may, at the same time, be boosted by ritonavir leading to carbamazepine-related toxicity 9 (see Table S1 ). 4 Greater risk of QT prolongation. Protease inhibitors could predispose individuals to QT prolongation and torsade de pointes 10 by dose-dependent block of human ether-a-go-go-related gene (HERG) potassium channels. Theoretically, coadministration with other agents that can prolong the QT intervaland the psychiatric pharmacopeia is full of QT prolongersmay result in additive effects and increased risk of ventricular arrhythmias, including torsade de pointes and sudden death. Disclosure statement Global Cases by the Center for Systems Science and Engineering A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 HIV-1 protease inhibitors. A review for clinicians Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir Drugs as P-glycoprotein substrates, inhibitors, and inducers Pharmacotherapy considerations in patients with HIV and psychiatric disorders: Focus on antidepressants and antipsychotics Indinavir concentrations and St John's wort Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir Blockade of HERG channels by HIV protease inhibitors The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This article was supported by the research projects: the authors received no financial support for the research, authorship, and/or publication of this article.